Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27501698 | 0.86 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL17358769 | 0.85 | LSS (0.98) | LSSMEN1KMT2A | |
| SCHEMBL17358774 | 0.82 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL7688275 | 0.82 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL7687634 | 0.81 | LSS (0.68) | LSSMEN1KMT2A | |
| SCHEMBL3674881 | 0.81 | LSS (1.00) | LSSMEN1KMT2A | |
| Bromide SCHEMBL7685880 | 0.80 | LSS (0.98) | LSSMEN1KMT2A | |
| SCHEMBL7681749 | 0.79 | LSS (0.71) | LSSMEN1KMT2A | |
| SCHEMBL7681910 | 0.79 | LSS (0.65) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL29455114 | 0.78 | LSS (1.00) | LSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441177-B1 | Tertiary amines | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | claimed |
| EP-0778264-B1 | Tertiary amines having antimycotic and cholesterol lowering activity | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | claimed |
| US-6034275-A | FUGICIDES; ATICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-03-07 | — | — | US | claimed |
| CN-1158844-A | Tertiary amines | HOFFMANN LA ROCHE (CH) | 1997-09-10 | — | — | CN | claimed |
| EP-0778264-A1 | Tertiary amines having antimycotic and cholesterol lowering activity | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | claimed |
| EP-2866810-B9 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | UNIV MISSOURI (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| US-6441177-B1 | Tertiary amines | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0778264-B1 | Tertiary amines having antimycotic and cholesterol lowering activity | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| CN-1067991-C | Aminoalkyl subsetd. benzo-heterocyclic compounds | HOFFMANN LA ROCHE (CH) | 2001-07-04 | — | — | CN | disclosed |
| US-6034275-A | FUGICIDES; ATICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-03-07 | — | — | US | disclosed |
| CN-1161328-A | Aminoalkyl subsetd. benzo-heterocyclic compounds | HOFFMANN LA ROCHE (CH) | 1997-10-08 | — | — | CN | disclosed |
| EP-0778264-A1 | Tertiary amines having antimycotic and cholesterol lowering activity | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | ESRRA, ESRRB, ESRRG | LSS 276/4885MEN1 4535/4885KMT2A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.